Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved symbols : Jagx save search
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Published: 2023-10-18 (Crawled : 13:00) - biospace.com/
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -4.27%
H: 8.4%
C: 5.92%
drug conference association care pharmaceuticals
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-07-26 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 2.57%
H: 11.58%
C: 6.27%
diarrhea health approval treatment trial
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
Published: 2023-07-07 (Crawled : 21:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
| Email alert
Add to watchlist
health approval meeting
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Published: 2023-05-11 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 23.61%
H: 37.08%
C: 7.87%
fda drug diarrhea approved animal
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
Published: 2023-05-10 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 1.82%
H: 35.12%
C: 4.06%
drug health
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-03-30 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -2.24%
H: 9.03%
C: -2.56%
fda veterinary drug conference diarrhea health approved animal cancer
Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
Published: 2023-03-13 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -5.17%
H: 3.64%
C: -0.91%
drug health
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
Published: 2023-02-23 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 3.91%
H: 1.5%
C: -9.4%
fda drug patent health approved crofelemer
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
Published: 2023-01-25 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 3.23%
H: 2.93%
C: -2.94%
health approved crofelemer milestone
Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs
Published: 2022-05-03 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 2.18%
H: 2.17%
C: -0.41%
drug diarrhea health approval
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Published: 2022-02-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -0.76%
H: 0.75%
C: -8.75%
health drug approval diarrhea crofelemer
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2021-12-22 (Crawled : 15:00) - biospace.com/
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -1.15%
H: 0.47%
C: -3.72%
diarrhea application therapy drug approval crofelemer
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2021-09-23 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: 4.8%
H: 4.58%
C: 1.67%
fda diarrhea therapy approval crofelemer
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.